The field of medicine is filled with transformational technologies that have radically altered disease treatment. From sterile techniques to blood transfusions, vaccines and antibiotics, medical technology continues to change our lives. A more recent development involves the treatment of valvular heart disease, which has been radically altered by the FDA’s approval of transcatheter aortic valve replacement (TAVR).
TAVR is an option for patients with severe aortic stenosis whose symptoms are inoperable or who are at high risk for standard surgical valve replacement. The first FDA approval of a TAVR device was in 2011 and the second came in 2014. The professional societies for cardiology and cardiac surgery worked together to develop the national Transcatheter Valve Therapy (TVT) registry for transcatheter valve patients. The first report from the registry was published in late 2013, with results for morbidity and mortality comparable to those outcomes during clinical trials. For more information on TAVR and other minimally invasive valve therapies, please access the Winter 2014 edition of The Source newsletter for Physician members of HealthTrust.
SourceTrust stays abreast of transformational technology in multiple specialties through review of clinical trial results in peer-reviewed journals and FDA postings. Up-to-date white papers are available to keep providers informed about the latest life-altering technologies.